Lipocine LPCN 深 滬
已收盤 11-06 16:00:00 美东时间
1.57
+0.040
+2.61%
華盛通- 最 高1.63
- 今 開1.59
- 成交量 50.97万股
- 最 低 1.50
- 昨 收 1.53
- 總市值 1294.35万
- 52周最高 12.37
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 1.36
- 委 比 -43.49%
- 總股本 824.43万
- 歷史最高 340.00
- 量 比 2.37
- 振 幅 8.50%
- 歷史最低 1.36
- 每 手 1
- 風險率 2.85%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lipocine Q3 EPS $(0.08) Beats $(0.32) Estimate, Sales $2.290M Beat $159.500K Estimate
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.32) by 75 percent. This is a 86.44 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $2.290 million which bea...
11-05 21:23
Lipocine Updates Investor Presentation to Reflect Strategy
Lipocine ( ($LPCN) ) has shared an update. Lipocine has updated the corporate p...
10-20 20:17
Lipocine Licensing Partner Verity Pharmaceuticals Receives Health Canada Approval For TLANDO Capsules For Testosterone Replacement Therapy In Adult Males
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine’s licensing partner Verity Pharmaceuticals Inc (Verity Pharma), Health Canada has approved TLANDO® (testosterone undecanoate) capsules for tes...
10-07 18:25
Insiders Pile Into Lipocine, Prothena, Pampa, AFC Gamma, ASP
Insiders have been trading these 5 stocks: (($LPCN)), (($PRTA)), (($PAM)), (($A...
10-03 21:01
美股大行评级 | 麦当劳目标价遭下调至320美元！现价仍有近3成上涨空间；戴尔、迈威尔、微软齐获机构看好
今日重点评级关注：HC Wainwright & Co.：维持Gossamer Bio"买入"评级，目标价从2美元升至90美元；巴克莱：维持Ultragenyx Pharmaceutical"超配"评级，目标价从32美元升至35美元
09-22 16:25
HC Wainwright & Co. Reiterates Neutral on Lipocine, Announces $4 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Neutral and announces $4 price target.
09-22 00:36
Lipocine Updates Sales Agreement Fee Structure with A.G.P.
Lipocine ( ($LPCN) ) has shared an update. On September 8, 2026, Lipocine Inc. ...
09-11 18:29
Lipocine 2026年第二季度财报：许可收入缺失拖累营收
Lipocine（LPCN）2026年第二季度营收19.0万美元，同比下降约69.5%；净亏损扩大至262.3万美元，稀释每股亏损收窄至0.32美元，LPCN 1154三期主要终点未达标。
08-05 07:13
Lipocine Q2 EPS $(0.32) Beats $(0.43) Estimate, Sales $190.099K Beat $156.500K Estimate
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.43) by 25.58 percent. This is a 21.95 percent increase over losses of $(0.41) per share from the same period last year. The company reported quarterly sales of $190.099 thousand whi...
08-04 18:19
Lipocine Appoints Industry Veteran Grissinger to Board
Lipocine ( ($LPCN) ) has provided an announcement. On August 3, 2026, Lipocine ...
08-03 21:57
